-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! A Project by Shijiazhuang Sihua Pharmaceutical Group Selected as an Outstanding Smart Manufacturing Scenario at the National Level
Category:
发布时间：2023-01-04
【概要描述】
Recently, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation jointly released the list of demonstration smart manufacturing factories and outstanding application scenarios for 2022. The digital R&D and design project for pharmaceutical products submitted by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was selected as an outstanding smart manufacturing scenario for 2022.
Recently, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation jointly released the list of demonstration smart manufacturing factories and outstanding application scenarios for 2022. Among them, the digital R&D and design project for pharmaceutical products submitted by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was selected as an outstanding smart manufacturing scenario for 2022.
Over the past two years, Shijiazhuang Sihua Pharmaceutical has focused on the cutting edge of science, technology, and the market, leveraging digital R&D and design to tackle critical “bottleneck” technologies. As a result, R&D efficiency has increased substantially, the pace of intelligent industrialization has accelerated markedly, and the company’s innovative, high-quality development has been robustly advanced. In 2022, Sihua Pharmaceutical ranked among the industry leaders in both the number of approved generic drugs and the number of applications submitted for approval.
According to the head of the R&D Center at Shijiazhuang Fourth Pharmaceutical, digital transformation has become a prevailing trend in pharmaceutical companies’ product development and intelligent manufacturing. In every stage of drug R&D—ranging from digitalization of research and experimentation and clinical data mining to real-world studies, pharmacovigilance, digital therapeutics, and market data insights—deep big-data analytics is indispensable. Particularly with the application of AI-driven big-data analytics, numerous R&D barriers in areas such as drug structure design, target identification and validation, lead-compound optimization, candidate drug development, and clinical trials can be effectively addressed. Digital technologies are reshaping the approach to drug discovery and development, enabling sophisticated biological simulations, significantly boosting the efficiency of R&D success, substantially reducing R&D costs, and enhancing the effectiveness of translating innovative discoveries into commercial outcomes.
According to reports, in order to implement the “14th Five-Year Plan for Intelligent Manufacturing Development,” the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation have jointly launched the 2022 Pilot and Demonstration Initiative for Intelligent Manufacturing. This initiative aims to select a number of outstanding intelligent manufacturing scenarios, establish a group of demonstration smart factories through a “challenge-based recruitment” approach, cultivate leading enterprises across various industries and fields, and promote the high-quality development of intelligent manufacturing.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091